These metabolic disorders, which accompany AD even from its early stages [26,127], lead to exacerbations of insulin signaling disorders, glucose use and insulin resistance problems [20,34,128], such as decreased acetylcholine (ACh) levels [20], with further aggravation of the pathological condition for those carrying the genetic risk factor APOE4. The gene discussed is APOE; the disease is Alzheimer disease.